Ranpirnase interferes with NF-κb pathway and MMP9 activity, inhibiting malignant mesothelioma cell invasiveness and xenograft growth

Genes and Cancer

Volumn 2, Issue 5, 2011, Pages 576-584

  Nasu, Masaki ^a,b   Carbone, Michele ^a,c   Gaudino, Giovanni ^a   Ly, Bevan H ^a   Bertino, Pietro ^a   Shimizu, David ^c   Morris, Paul ^d   Pass, Harvey I ^e   Yang, Haining ^a,c  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d QUEEN S MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

mesothelioma; MMP9; NF B; ranpirnase; TNF

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RANPIRNASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT; ZYMOGRAPHY;

MUS;

EID: 80053020945     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911412375     Document Type: Article

References (35)

1. Sebbag G,Sugarbaker PH.Peritoneal mesothelioma proposal for a staging system.Eur J Surg Oncol. 2001;27 (3): 223-4.
2. Ismail-Khan R,Robinson LA,Williams CC,Garrett CR,Bepler G,Simon GR.Malignant pleural mesothelioma: a comprehensive review.Cancer Control. 2006;13 (4): 255-63.
3. Moolgavkar SH,Meza R,Turim J.Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005.Cancer Causes Control. 2009;20 (6): 935-44.
4. Carbone M,Albelda SM,Broaddus VC, et al.Eighth international mesothelioma interest group. Oncogene 2007;26(49):6959-67.
5. Flores RM,Pass HI,Seshan VE, et al.Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.J Thorac Cardiovasc Surg. 2008;135 (3): 620-6.
6. Kaufman AJ,Pass HI.Current concepts in malignant pleural mesothelioma.Expert Rev Anticancer Ther. 2008;8 (2): 293-303.
7. Ardelt W,Mikulski SM,Shogen K.Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos: homology to pancreatic ribonucleases.J Biol Chem. 1991;266 (1): 245-51.
8. Porta C,Paglino C,Mutti L.Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.Biologics. 2008;2 (4): 601-9.
9. Pavlakis N,Vogelzang NJ.Ranpirnase-an antitumour ribonuclease: its potential role in malignant mesothelioma.Expert Opin Biol Ther. 2006;6 (4): 391-9.
10. Costanzi J,Sidransky D,Navon A,Goldsweig H.Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.Cancer Invest. 2005;23 (7): 643-50.
11. Tsai SY,Ardelt B,Hsieh TC,Darzynkiewicz Z,Shogen K,Wu JM.Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB.Int J Oncol. 2004;25 (6): 1745-52.
12. Ita M,Halicka HD,Tanaka T, et al.Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines.Cancer Biol Ther. 2008;7 (7): 1104-8.
13. Beck AK,Pass HI,Carbone M,Yang H.Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.Future Oncol. 2008;4 (3): 341-9.
14. Mikulski SM,Costanzi JJ,Vogelzang NJ, et al.Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.J Clin Oncol. 2002;20 (1): 274-81.
15. Reck M,Krzakowski M,Jassem J, et al.Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM) [abstract].J Clin Oncol. 2009;27:15s.
16. Yang H,Bocchetta M,Kroczynska B, et al.TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis.Proc Natl Acad Sci U S A. 2006;103 (27): 10397-402.
17. Yang H,Rivera Z,Jube S, et al.Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.Proc Natl Acad Sci U S A. 2010;107 (28): 12611-6.
18. Kroczynska B,Cutrone R,Bocchetta M, et al.Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters.Proc Natl Acad Sci U S A. 2006;103 (38): 14128-33.
19. Li W,Li H,Bocking AD,Challis JR.Tumor necrosis factor stimulates matrix metalloproteinase 9 secretion from cultured human chorionic trophoblast cells through TNF receptor 1 signaling to IKBKB-NFKB and MAPK1/3 pathway.Biol Reprod. 2010;83 (3): 481-7.
20. Bertino P,Piccardi F,Porta C, et al.Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.Clin Cancer Res. 2008;14 (2): 541-8.
21. Luo JL,Maeda S,Hsu LC,Yagita H,Karin M.Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression.Cancer Cell. 2004;6 (3): 297-305.
22. Ea CK,Baltimore D.Regulation of NF-kappaB activity through lysine monomethylation of p65.Proc Natl Acad Sci U S A. 2009;106 (45): 18972-7.
23. Lin Y,Bai L,Chen W,Xu S.The NF-kappaB activation pathways: emerging molecular targets for cancer prevention and therapy.Expert Opin Ther Targets. 2010;14 (1): 45-55.
24. Sartore-Bianchi A,Gasparri F,Galvani A, et al.Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.Clin Cancer Res. 2007;13 (19): 5942-51.
25. Lee I.Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008;8 (6): 813-27.
26. Deptala A,Halicka HD,Ardelt B, et al.Potentiation of tumor necrosis factor induced apoptosis by onconase.Int J Oncol. 1998;13 (1): 11-6.
27. Goparaju CM,Blasberg JD,Volinia S, et al.Onconase mediated NFKbeta downregulation in malignant pleural mesothelioma.Oncogene.
28. Grabarek J,Ardelt B,Du L,Darzynkiewicz Z.Activation of caspases and serine proteases during apoptosis induced by Onconase (ranpirnase).Exp Cell Res. 2002;278 (1): 61-71.
29. Johansson N,Ahonen M,Kahari VM.Matrix metalloproteinases in tumor invasion.Cell Mol Life Sci. 2000;57 (1): 5-15.
30. McCawley LJ,Matrisian LM.Matrix metalloproteinases: they're not just for matrix anymore!.Curr Opin Cell Biol. 2001;13 (5): 534-40.
31. Egeblad M,Werb Z.New functions for the matrix metalloproteinases in cancer progression.Nat Rev Cancer. 2002;2 (3): 161-74.
32. Deryugina EI,Quigley JP.Matrix metalloproteinases and tumor metastasis.Cancer Metastasis Rev. 2006;25 (1): 9-34.
33. Martin MD,Matrisian LM.The other side of MMPs: protective roles in tumor progression.Cancer Metastasis Rev. 2007;26 (3-4): 717-24.
34. Ramos-Nino ME,Vianale G,Sabo-Attwood T, et al.Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.Mol Cancer Ther. 2005;4 (5): 835-42.
35. Altomare DA,Rybak SM,Pei J, et al.Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.BMC Cancer. 2010;10:34.